This site uses cookies to bring you the best experience. Find out more
Skip to main content


Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on if you would like to know more about any of these stories.

You can also follow us on X or LinkedIn  

Vaccitech Awarded BARDA contract valued at $8.5M to conduct Phase II trial for Influenza Vaccine

Oxford, UK – 4 March 2019 Vaccitech announced today that it has been awarded a contract valued at $8.5 million from the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, for the advanced clinical development of its recombinant Modified Vaccinia Ankara (MVA) vaccine candidate for prevention of seasonal... Read more

First production and administration of Axumin (fluciclovine (18F)) in Italy

Oxford, UK – February 12, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the first commercial production of Axumin® (fluciclovine (18F)) in Italy occurred recently, with the first Italian patients being dosed.  Axumin is a novel molecular imaging agent approved in the European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected... Read more

The Oxford Science Park sponsors the OXBA Innovation Award for the fourth year

Apply now to be recognised as one of Oxfordshire’s best businesses Oxford, UK, 14 January 2019  – Oxfordshire companies which are progressing valuable innovations can apply now for The Oxford Science Park Innovation Award, one of 2019’s Oxfordshire Business Awards (OXBA). The Oxford Science Park, one of the UK’s leading parks for science and technology companies, is pleased to be sponsoring the award for the fourth year. In the winning... Read more

The Daubeny Project

Imaginative design, inspiring spaces.